The GRDP initiative will share regulatory review materials with global health authorities to accelerate access to medicines worldwide.
The GRDP initiative will share regulatory review materials with global health authorities to accelerate access to medicines worldwide.
The warning for NAION risk applies to all GLP-1 medications, including popular weight loss drugs Ozempic, Wegovy, Mounjaro, and Zepbound.
CMS to select up to 20 additional drugs covered under Part D and/or payable under Part B, plus select drugs for price renegotiation.
They will investigate the supply chain that supports US drug manufacturing.
The agency’s CBER recommends building potency assurance into every stage of a therapy’s lifecycle.
Research links higher launch prices with ongoing access challenges, highlighting coverage restrictions and affordability concerns for patients.
New Commerce Department guidance outlines narrow exemptions to 100% drug import tariffs, covering specialty therapies from 19 countries.
New pharmaceutical rules aim to expand medicine access, strengthen supply security, and reshape incentives for EU innovation.